Clinuvel Pharmaceuticals' New Drug Submission Under Health Canada Review

MT Newswires Live12-23 08:40

Clinuvel Pharmaceuticals (ASX:CUV) said its new drug submission to Health Canada for its photoprotective therapy Scenesse was validated and accepted for review ahead of the regulator's target validation window, according to a Monday filing with the Australian bourse.

Scenesse was designed to prevent phototoxicity in adult patients with erythropoietic protoporphyria an inherited metabolic disorder.

The submission is now under review by Health Canada's Health Products and Food Branch, which has a 300-day target to complete its evaluation and issue a marketing authorization decision, the filing said. A decision is expected by the fourth quarter of 2025.

Clinuvel Pharmaceuticals shares rose nearly 1% in morning trade Monday.

Price (AUD): $11.90, Change: $+0.11, Percent Change: +0.93%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493279189?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 08:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493279189","market":"sg","top_or_hot":-1,"title":"Clinuvel Pharmaceuticals' New Drug Submission Under Health Canada Review","media":"MT Newswires Live","content":"<html><body><p> Clinuvel Pharmaceuticals (ASX:CUV) said its new drug submission to Health Canada for its photoprotective therapy Scenesse was validated and accepted for review ahead of the regulator's target validation window, according to a Monday filing with the Australian bourse.</p><p>Scenesse was designed to prevent phototoxicity in adult patients with erythropoietic protoporphyria an inherited metabolic disorder.</p><p>The submission is now under review by Health Canada's Health Products and Food Branch, which has a 300-day target to complete its evaluation and issue a marketing authorization decision, the filing said. A decision is expected by the fourth quarter of 2025.</p><p>Clinuvel Pharmaceuticals shares rose nearly 1% in morning trade Monday.</p><p>Price (AUD): $11.90, Change: $+0.11, Percent Change: +0.93%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinuvel Pharmaceuticals' New Drug Submission Under Health Canada Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinuvel Pharmaceuticals' New Drug Submission Under Health Canada Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-23 08:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clinuvel Pharmaceuticals (ASX:CUV) said its new drug submission to Health Canada for its photoprotective therapy Scenesse was validated and accepted for review ahead of the regulator's target ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0994945656.USD","symbol_name":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493279189","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493279189","pubTimestamp":1734914404,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clinuvel Pharmaceuticals  said its new drug submission to Health Canada for its photoprotective therapy Scenesse was validated and accepted for review ahead of the regulator's target validation window, according to a Monday filing with the Australian bourse.Scenesse was designed to prevent phototoxicity in adult patients with erythropoietic protoporphyria an inherited metabolic disorder.The submission is now under review by Health Canada's Health Products and Food Branch, which has a 300-day target to complete its evaluation and issue a marketing authorization decision, the filing said. A decision is expected by the fourth quarter of 2025.Clinuvel Pharmaceuticals shares rose nearly 1% in morning trade Monday.Price : $11.90, Change: $+0.11, Percent Change: +0.93%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","BK7508":"医药生物股","LU0426417589.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC","BK7067":"生物科技","BK4125":"广播","CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC","AUD":"Audacy Inc.","LU2238339852.HKD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (HKD) ACC","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC"},"translate_title":"Clinuvel Pharmaceuticals提交的新药接受加拿大卫生部审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"CUV.AU":0.9},"content_text":"Clinuvel Pharmaceuticals (ASX:CUV) said its new drug submission to Health Canada for its photoprotective therapy Scenesse was validated and accepted for review ahead of the regulator's target validation window, according to a Monday filing with the Australian bourse.Scenesse was designed to prevent phototoxicity in adult patients with erythropoietic protoporphyria an inherited metabolic disorder.The submission is now under review by Health Canada's Health Products and Food Branch, which has a 300-day target to complete its evaluation and issue a marketing authorization decision, the filing said. A decision is expected by the fourth quarter of 2025.Clinuvel Pharmaceuticals shares rose nearly 1% in morning trade Monday.Price (AUD): $11.90, Change: $+0.11, Percent Change: +0.93%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493279189"}